Unknown OBSERVATIONAL NCT03613337

Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention

Sponsor: Cui Yimin

Conditions Clopidogrel Coronary Heart Disease Genetic Risk Factors Percutaneous Coronary Intervention Restenosis Smoking Status

Interventions clinical restenosis

Updated 7 times since 2018 Last updated: Mar 1, 2020 Started: May 1, 2018 Primary completion: Jul 31, 2020 Completion: Aug 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03613337, this observational or N/A phase trial focuses on Clopidogrel and Coronary Heart Disease and remains ongoing. Sponsored by Cui Yimin, it has been updated 7 times since 2018, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Apr 2022 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jan 2021 — Apr 2022 [monthly]

Recruiting
Apr 2020 — Jan 2021 [monthly]

Recruiting

▶ Show 2 earlier versions

Oct 2018 — Apr 2020 [monthly]

Recruiting
Sep 2018 — Oct 2018 [monthly]

Recruiting

First recorded

May 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cui Yimin

Data source: Peking University First Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China